The effect of colestipol and cholestyramine on ibuprofen bioavailability in man

The purpose of this study was to determine whether a concomitant single oral dose of one of the anion exchange resins colestipol hydrochloride (10 g) or cholestyramine (8 g) administered with ibuprofen (400 mg) would alter the bioavailability of this non‐steroidal anti‐inflammatory agent. The study was performed according to a randomized three‐way crossover design in six healthy male volunteers. After dosing, serial blood samples were collected for a period of 10 h. Plasma harvested from blood was analysed for ibuprofen by a sensitive high‐performance liquid chromatographic method. There were no significant differences between colestipol treatment and control for peak plasma concentration (Cmax), time to peak concentration (Tmax), area under the plasma concentration—time curve (AUC), mean residence time (MRT), elimination rate constant (Kel), or elimination half‐life (t1/2). Cholestyramine treatment resulted in a significant decrease in AUC (26%, p< 0.05) and Cmax (34.4%, p <0.01) and a significant increase in Tmax (80%, p < 0.01) and MRT (20.2%, p < 0.05). Cholestyramine administration showed no significant effect on the Kel and t1/2 values. A significant correlation was obtained between the increase in MRT and the increase in Tmax. The confidence intervals (90%) of the mean values of the pharmacokinetic parameters (AUCO–∞ and Cmax) for the colestipol : control ratio were well within the acceptable range of 100 ± 20, whereas those for the cholestyramine : control ratio were outside it. Colestipol treatment was found to be bioequivalent to the control treatment by Schuirmann's two one‐sided t tests, while cholestyramine treatment was found to be bioinequivalent. The results indicate a lack of interaction between ibuprofen and colestipol and a potential significant interaction (decrease in rate and extent of absorption of ibuprofen) between cholestyramine and ibuprofen in patients receiving concurrent therapy.

[1]  Y. El‐Sayed,et al.  The effect of colestipol and cholestyramine on the systemic clearance of intravenous ibuprofen in rabbits , 1994, The Journal of pharmacy and pharmacology.

[2]  X. Zhu,et al.  Polymeric sorbents for bile acids. I: Comparison between cholestyramine and colestipol. , 1992, Journal of Pharmacy and Science.

[3]  Y. El‐Sayed,et al.  Interruption of the enterohepatic circulation of indomethacin by cholestyramine in rabbits , 1990 .

[4]  R. Herman,et al.  Disposition of lorazepam in human beings: Enterohepatic recirculation and first‐pass effect , 1989, Clinical pharmacology and therapeutics.

[5]  P. Neuvonen,et al.  Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. , 1988, British journal of clinical pharmacology.

[6]  B. Chanu [Drug treatment of hyperlipoproteinemia]. , 1987, Soins; la revue de reference infirmiere.

[7]  R. Verbeeck,et al.  Clinical Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs , 1983, Clinical pharmacokinetics.

[8]  B. Snider,et al.  Determination of flurbiprofen and ibuprofen in dog serum with automated sample preparation. , 1981, Journal of pharmaceutical sciences.

[9]  V. Payne,et al.  Use of Colestipol in a Patient with Digoxin Intoxication , 1981, Drug intelligence & clinical pharmacy.

[10]  K. Desante,et al.  The Effect of Colestipol Hydrochloride on the Bioavailability and Pharmacokinetics of Clofibrate , 1979, Journal of clinical pharmacology.

[11]  E. Jähnchen,et al.  Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine , 1977, Clinical pharmacology and therapeutics.

[12]  J. Caldwell,et al.  Interruption of the enterohepatic circulation of digitoxin by cholestyramine. II. Effect on metabolic disposition of tritium-labeled digitoxin and cardiac systolic intervals in man. , 1971, The Journal of clinical investigation.

[13]  J. Caldwell,et al.  Interruption of the enterohepatic circulation of digitoxin by cholestyramine. I. Protection against lethal digitoxin intoxication. , 1971, The Journal of clinical investigation.